M12 (Microsoft's Venture Fund) — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
1910 Genetics develops genetic engineering and biotechnology solutions, leveraging computational and biological approaches.
AI & Machine LearningBiotechDeep TechCambridge, US
Jennifer O. Nwankwo(Executive Officer, Director)
BoardSamir Kumar(Director)Marc Foster(Director)Jory Bell(Director)in
Co-investorsFoundersX VenturesPlayground GlobalY CombinatorEmles Venture PartnersAccenture Ventures
Arkose Labs provides fraud and bot protection for enterprises including banks, gaming platforms, fintechs, and marketplaces.
AI & Machine LearningCybersecurityEnterprise SoftwareSaaSSan Francisco, US
Kevin Gosschalk(CEO)inMark Resnick(Executive Officer)
BoardNagraj Kashyap(Director)James Wu(Director)inDafina Toncheva(Director)inJeremiah Grossman(Director)
PartnerJames Wu· led
Co-investorsAspenwoodBallistic VenturesSoftBank Vision FundSony Ventures CorporationTransition Level InvestmentsUS Venture Partners+2 more
Envisagenics uses AI-driven analysis of RNA splicing to discover novel drug targets for immuno-oncology and neurodegenerative diseases.
AI & Machine LearningBiotechMedical DevicesNew York, US
Maria Pineda, PhD(CEO & Co-founder)Martin Akerman, PhD(CEO & Co-founder)Martin Akerman(Executive Officer, Director, Promoter)Maria Luisa Pineda(Executive Officer, Director, Promoter)Maria Luisa Pineda, PhD.(Founder)in
Co-investorsDynamk CapitalHAWKTAILMadrona Venture GroupRed Cell IncubationDolby Family VenturesThird Kind Venture Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.